Daniel Millard

Cooley advised Feedzai, a global leader in fraud and financial crime prevention, on its acquisition of Demyst, including Demyst’s Zonic data workflow orchestration platform, intellectual property and sophisticated data-integration capabilities.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised UiPath (NYSE: PATH), a leading enterprise automation and artificial intelligence (AI) software company, on its acquisition of Peak, an AI-native company based in Manchester, United Kingdom.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised Cresta, an end-to-end generative artificial intelligence (AI) platform for contact centers, on the closing of its $125 million Series D.